Evidence map›Paper›PMID 24382714›Full record

ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2014

High-throughput flow cytometry data normalization for clinical trials.

Greg Finak, Wenxin Jiang, Kevin Krouse, Chungwen Wei, Ignacio Sanz, Deborah Phippard, Adam Asare, Stephen C De Rosa, Steve Self, Raphael Gottardo

Abstract read
In one paragraph

Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 46 citations in OpenAlex.

  1. CytoBatchFlagR: A Comprehensive Framework to Objectively Assess High-Parameter Cytometry Data for Batch Effects.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. CytoPy: An autonomous cytometry analysis framework.PLoS computational biology · 2021
    Article
  10. Article
  11. Review
  12. Review
  13. CytoNorm: A Normalization Algorithm for Cytometry Data.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2020
    Article
  14. Review
  15. Article
  16. Supervised Machine Learning with CITRUS for Single Cell Biomarker Discovery.Methods in molecular biology (Clifton, N.J.) · 2019
    Article
  17. Data-Driven Flow Cytometry Analysis.Methods in molecular biology (Clifton, N.J.) · 2019
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Greg FinakVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109.
Wenxin Jiang
Kevin Krouse
Chungwen Wei
Ignacio Sanz
Deborah Phippard
Adam Asare
Stephen C De Rosa
Steve Self
Raphael Gottardo
Fred Hutch Cancer Center · USEmory University · USImmune Tolerance Network · USUniversity of Washington · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI JEREMY M. BOSS · 2014 to 2026
$76.6M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials NetworkU01AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SELF, STEVEN G. · 2006 to 2010
$53.8M
Role of B Cells in Synovial Inflammation & LN Remodeling in RA ArthritisP01AI078907 · NIAID · UNIVERSITY OF ROCHESTER · PI LUND, FRANCES E. · 2010 to 2014
$10.8M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
The Statistical and Computational Analysis of Flow Cytometry DataR01EB008400 · NIBIB · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOTTARDO, RAPHAEL · 2008 to 2015
$2.9M
IMMUNE TOLERANCE NETWORK-266015416-266015416N01AI015416 · NIAID · REGENTS OF THE UNIVERSITY OF C · PI BLUESTONE, JEFFREY A · 2002 to 2006
–
NIAID NIH HHS N01 AI015416NIAID NIH HHS P01 AI078907NIAID NIH HHS P30 AI027757NIAID NIH HHS R37 AI049660NIAID NIH HHS U01 AI068635NIAID NIH HHS U19 AI110483NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIBIB NIH HHS R01 EB008400
6 · The paper itself

Abstract

Flow cytometry datasets from clinical trials generate very large datasets and are usually highly standardized, focusing on endpoints that are well defined apriori. Staining variability of individual makers is not uncommon and complicates manual gating, requiring the analyst to adapt gates for each sample, which is unwieldy for large datasets. It can lead to unreliable measurements, especially if a template-gating approach is used without further correction to the gates. In this article, a computational framework is presented for normalizing the fluorescence intensity of multiple markers in specific cell populations across samples that is suitable for high-throughput processing of large clinical trial datasets. Previous approaches to normalization have been global and applied to all cells or data with debris removed. They provided no mechanism to handle specific cell subsets. This approach integrates tightly with the gating process so that normalization is performed during gating and is local to the specific cell subsets exhibiting variability. This improves peak alignment and the performance of the algorithm. The performance of this algorithm is demonstrated on two clinical trial datasets from the HIV Vaccine Trials Network (HVTN) and the Immune Tolerance Network (ITN). In the ITN data set we show that local normalization combined with template gating can account for sample-to-sample variability as effectively as manual gating. In the HVTN dataset, it is shown that local normalization mitigates false-positive vaccine response calls in an intracellular cytokine staining assay. In both datasets, local normalization performs better than global normalization. The normalization framework allows the use of template gates even in the presence of sample-to-sample staining variability, mitigates the subjectivity and bias of manual gating, and decreases the time necessary to analyze large datasets.

Indexed as

AlgorithmsClinical Trials as TopicFlow CytometryAIDS VaccinesCytokinesHumansSoftwareStatistics as TopicAIDS VaccinesCytokinesbiasBioConductorimmunologystaining variabilitytemplate gating

Identifiers

PMID24382714
PMCPMC3992339
OpenAlexW1539153878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.